Adtalem Global Education Inc. (NYSE:ATGE) Q1 2024 Earnings Call Transcript

Adtalem Global Education Inc. (NYSE:ATGE) Q1 2024 Earnings Call Transcript October 26, 2023

Adtalem Global Education Inc. beats earnings expectations. Reported EPS is $0.93, expectations were $0.82.

Operator: Greetings, and welcome to the Adtalem Global Education’s First Quarter Fiscal Year 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jonathan Spitzer, VP of IR. Thank you, Jonathan. You may begin.

Jonathan Spitzer: Good afternoon, ladies and gentlemen, and welcome to our earnings call for the first quarter 2024 results. On the call with me today are Steve Beard, President and Chief Executive Officer of Adtalem Global Education, and Bob Phelan, Chief Financial Officer. Before I hand you over to Steve, I will as usual take you through the legal Safe Harbor and cautionary declarations. Certain statements and projections of future results made in this presentation constitute as forward-looking statements that are based on current — our current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. We undertake no obligation to update publicly any forward-looking statement after this presentation, whether as a result of new information, future events, changes in assumptions or otherwise.

Please see latest Form 10-K and Form 10-Q for a discussion of risk factors as it relates to forward-looking statements. In today’s presentation, we’ll use certain non-GAAP financial measures. We refer you to the appendix in the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information. You will find a link to the webcast on our Investor Relations website at investor.adtalem.com. After this call, the presentation and webcast will be archived on the website for 30 days. I will now hand you over to Steve.

Steve Beard: Good afternoon, everyone, and thank you for taking the time to join our first quarter fiscal year 2024 earnings call. We delivered a strong quarter as our growth with purpose strategy, a 3-year initiative focused on driving organic revenue growth has delivered top and bottom line results ahead of our expectations. It has also returned us to total enrollment growth while continuing to deliver outstanding student outcomes. In the first quarter of fiscal 2024, revenue was $369 million, up 4% versus prior year and adjusted earnings per share was $0.93, up 3% versus prior year. Accelerating performance across our five operational pillars, marketing, enrollment, retention, pricing and programs affords us the opportunity to capitalize on our market-leading scale and our market responsive health care focus.

Our emphasis on enhancing the student experience and investing in innovative and differentiated capabilities is showing up in our quality measures, our academic outcomes and improved persistence rates. As a result, our talent graduates are highly employable and attractive in-demand professions and far less likely to default in their student loans compared to their counterparts at postsecondary institutions, private, public and for profit alike. Our brand campaigns that launched last fiscal year are delivering incremental spend efficiencies and organic increase this quarter as we optimize our use of data-driven tools and methods. Our successful execution has resulted in double-digit inquiry growth year-over-year at all of our institutions. In addition to optimizing our marketing capabilities, we are simplifying and streamlining student application experience to make admissions as user friendly as possible.

These efforts have driven encouraging results with increased year-over-year application conversion rates. Moving on to results by segment. Across our five institutions, we are striking an optimal balance between investing to accelerate near-term performance and expanding profitability over the long-term. Chamberlain and Walden were the primary drivers of our strong performance in the first quarter, and we remain confident that the financial performance of those institutions will continue to accelerate for the balance of the fiscal year. In the Med/Vet segment, Ross University School of Veterinary Medicine continues to operate near capacity. As for our medical schools, we diagnosed the conversion challenges and are executing remediation efforts to return those institutions to growth.

Based on early indications, we expect total enrollment trends to improve over the remainder of the fiscal year. Adtalem’s brand recognition combined with its ability to scale, in-demand programs and innovative specialized nursing curriculum continues to position it as the leading school of nursing in the U.S. Our campus-based pre-licensure Bachelor Science and Nursing degree program continues to resonate with over 12,500 students enrolled. We recently launched BSN online option, achieved year-over-year triple-digit growth and is swiftly approaching 1,000 students. The next generation NCLEX exam is now being administered to pre-licensure students, and we are leveraging proprietary adaptive learning technology to prepare our BSN students for the exam.

Additionally, our Practice-Ready Specialty-Focused model, coupled with our social determinants of learning framework, is creating an unparalleled offering in nursing education. Practice-Ready Specialty-Focused has provided specialized training to more than 1,000 BSN students through a proprietary learning model that better prepares students for the specialty work they will take on within U.S. health care. We’ve expanded this program to all 23 training campuses, broadening access for our students, while addressing areas of acute nursing shortages. At Walden, we’ve made significant progress toward regaining our leadership position in online education. Our brand investments and shifts in marketing mix continue to show momentum in new student growth, which is up double digits year-over-year for the second straight quarter.

This successful execution has resulted in elevated demand at Walden led by our health care programs, specifically social and behavioral sciences and nursing. We continue to invest in expanding these programs, which we believe positions us for long-term growth. Thanks in part to enhance data-driven marketing capabilities, Walden’s competency-based Tempo program grew new enrollments by 50% year-over-year. Also of note, Walden’s 69th commencement conferred more than 6,500 doctoral, masters and bachelors degrees to students from all 50 states and to more than 40 countries. Nearly 35% of those degrees were for post-licensure nursing programs. And we are especially proud to say that more than half of the graduates who reported their race identified as being from underrepresented minority groups.

Ross Vet continues to operate near capacity, addressing the critical need for veterinarians in the U.S. and through our Growth with Purpose strategy, we are executing on new initiatives designed to further scale our program to meet the needs of the animal health community in the U.S. At our medical schools, we’ve identified opportunities for improving performance and are executing on remediation plans, including the restructuring of our enrollment and academic support teams to enhance the student journey. Starting in October to meet the needs of our medical students, we commenced a 10-week Capstone program designed to improve their preparedness for the step 1 USMLE exam, which then allows them to progress on to core clinicals. We are confident that the actions we’re taking at the medical schools will improve total enrollment trends over the course of this fiscal year.

A student concentrate on their laptop in the library, taking advantage of an educational program online. Editorial photo for a financial news article. 8k. –ar 16:9

As I said at the outset, our Growth with Purpose strategy is driving top and bottom line performance ahead of expectations. And we remain confident that these trends will accelerate over the course of the year. Accordingly, we are raising our fiscal 2024 guidance. We now expect revenue to be in the range of $1.47 billion to $1.53 billion and adjusted EPS to be in the range of $4.25 and to $4.45. We remain optimistic about our future and the foundation we’ve built for the students we serve. Adtalem is well-positioned for success as the leading health care educator and a systemically important component of U.S. health care. The successful execution of our Growth with Purpose initiatives drive enrollment, enhance student outcomes and to pose our graduates towards rewarding careers.

And this is what drives Adtalem’s impact on our communities, and we remain enthusiastic about what lies ahead. Now I’ll turn the call over to Bob for further discussion of our financial results.

Bob Phelan: Thanks, Steve, and hello, everyone. Our first quarter results reflect strong demand for our programs and our continued focus on enhanced student outcomes. I’ll begin with a review of our financial results and key drivers for our performance in the first quarter. Later in my remarks, I will discuss our expectations and assumptions for the balance of fiscal 2024. Starting with the top line. Revenue in the first quarter increased by 4.1% to $368.8 million driven by growth at Chamberlain and Walden, partially offset by Med/Vet, as our enterprise wide Growth with Purpose strategy accelerates. Consolidated adjusted operating income was $63.3 million compared with $66.8 million in the prior year. Adjusted EBITDA came in at $80.5 million, a decrease of 3.8% compared with the prior year, resulting in adjusted EBITDA margin of 21.8% or 180 basis points lower than prior year, as growth in revenue and operational efficiencies were offset by strategic investments in Growth with Purpose initiatives and other costs.

Adjusted net income for the quarter was $39.4 million, 5.3% lower compared to last year. Adjusted earnings per share was $0.93 or a 3.3% increase compared with the prior year. Diluted shares outstanding were 4.2 million lower compared to last year, resulting in first quarter diluted shares outstanding of 42.2 million. Next, I will discuss financial highlights by segment. Chamberlain reported first quarter revenue of $142.6 million, an increase of 5.3% when compared with the prior year, driven by growth in enrollment. Total student enrollment during the quarter increased 5.2% compared with the prior year as a result of continued growth in pre-licensure and post-licensure nursing programs as well as high persistence across the segment. Adjusted EBITDA decreased by 6.5% to $31.5 million as our underlying operational leverage was more than offset, primarily by investments in student support services to enhance student outcomes and other expenses.

We believe these investments will continue to deliver positive returns through higher future persistence rates and academic outcomes. Turning to Walden. Revenue during the quarter was $141.6 million, an increase of 8.2% when compared with the prior year, driven primarily by total student enrollment growth and the optimization of our tuition pricing model. Total student enrollment returned to growth this quarter, up 0.5% compared with the prior year as strong demand for our social and behavioral health and nursing programs continued to gain traction in addition to high persistence across the segment. Adjusted EBITDA increased 21% to $35.1 million as transformation and operational efficiencies are generating its intended leverage as we grow revenue.

For the Medical and Veterinary segment, revenue in the first quarter decreased 3.8% to $84.6 million. Total student enrollment decreased 7.5% compared with the prior year due to lower starts at the medical schools, partially offset by the veterinary school, which continues to operate near capacity. We are focused on our medical schools remediation plans to improve enrollment in our medical schools over the course of the fiscal year. Adjusted EBITDA decreased by 11.9% to $19.1 million due to lower revenue, partially offset by operational improvements as we execute on our medical schools remediation plans. Shifting to cash flow and the balance sheet. Our business continues to generate robust operating cash flow. Free cash flow during the quarter was $76 million, which was slightly lower year-over-year, driven primarily by higher CapEx spend of $15 million during the quarter, which is part of our Growth with Purpose strategy intended to improve student outcomes.

Reflecting our disciplined capital allocation philosophy, we maintained net leverage of 1.3x adjusted EBITDA with $708 million in long-term debt. Further, we returned $92 million in capital to our shareholders by repurchasing 2.2 million shares under our Board authorized share buyback program during the first quarter. Since the authorization of our $300 million program, we have repurchased shares worth approximately $219 million. Over approximately the last 18 months, we’ve repurchased roughly 10 million shares or approximately 20% of our shares outstanding. We believe these investments drive long-term intrinsic value for our shareholders. Turning to our guidance for fiscal 2024. As we accelerate performance through our Growth with Purpose strategy, we are raising our revenue guidance to be in the range of $1.47 billion to $1.53 billion, representing low to mid-single-digit year-over-year growth.

We are also raising our adjusted earnings per share guidance be in the range of $4.25 to $4.45, also reflecting low to mid-single-digit growth. We anticipate continuing to generate strong cash flow bolstering our balance sheet strength and providing us the ability to execute on our capital allocation philosophy. Let me provide additional context in relation to our fiscal 2024 outlook. We are forecasting total enrollment trends to continue to improve throughout the year, building on the higher first quarter total enrollment growth. And in turn, we still anticipate revenue to follow this trend with greater acceleration to occur in the back half of the year. As it relates to the phasing of our earnings during fiscal 2024, we continue to make incremental growth investments earlier in the year and are anticipating the second quarter to see a slightly higher investment level than the first quarter.

This does result in a short-term reduction to our adjusted EBITDA margin profile, specifically in the second quarter, but we anticipate growing our margin profile in the second half of the year, as revenue growth accelerates generating leverage, resulting in a full year adjusted EBITDA margin profile of approximately 24%, consistent with prior year and what we shared at our June 2023 Investor Day. Included within our raised fiscal ’24 guidance is the cost of an incremental $158 million letter of credit that will be placed in early November in accordance with request by the Department of Education. This new letter of credit will result in an annualized interest expense of approximately $6 million and will be placed through our availability on our existing revolver.

This has no material impact to our strategic plans nor does it impact our strong financial position, highlighted by our low net leverage and our healthy profitability levels and cash flow generation. In conclusion, our results demonstrate our ability to deliver short-term results, while sustainably investing in the long-term growth targets that we provided at our June 2023 Investor Day. I’m excited about the opportunities and the momentum our team is generating as a purpose driven organization, creating substantial value for our students and our shareholders. With that, I will now turn the call over to the operator for Q&A.

See also Renaissance Technologies Returns, AUM, CEO and Top Energy Stock Picks and Jim Cramer’s 10 Best AI Stocks.

Q&A Session

Operator: [Operator Instructions] Thank you. Our first question comes from the line of Jeff Meuler with Baird. Please proceed with your question.

Jeffrey Meuler: Yes, thank you. Good afternoon. Apologies if I missed it. Did you give Chamberlain new enrollment, or can you give some sense of how that’s trending?

Steve Beard: We did not. We referred to specific programs in the prepared remarks, but we did not give new enrollment at Chamberlain.

Jeffrey Meuler: Okay. I will ask maybe a little bit differently because you just had a 4% revenue growth quarter. You said you expect Chamberlain and Walden progress to continue to accelerate, those are your largest segments. And there was a comment I think about like Med continuing to improve over the balance of the year. And I know you raised your guidance, but the guidance has 1% growth at the low end, 3.5% growth at the midpoint. Both of those are lower than your Q1 growth. So I’m not — I guess I’m not understanding what you’re signaling because you’re talking about — you had a great quarter, you’re talking about things further improving and accelerating. And I don’t really see it in the guidance. I’m not sure what the disconnect is.

Steve Beard: Sure. So let me try to address that for you. What I would say is that we had very good first quarter, feel good about where we are going in terms of the improvements that we think we will be getting over the balance of the year. But it is the first quarter, so we are really early in the year and wanted to see a little bit longer trend before we take any numbers up further than what we did in the guidance at this point. The only other thing I would say is that when you get into the back half of the year, your comps are a little bit more difficult than what you had in the first quarter as well. So that’s another piece of what enters into that.

Jeffrey Meuler: Okay. And then I think there are some changes to gainful employment from your last quarter, and it looks like some of them are beneficial to the — some of the programs that you operate. So can you just address that for the audience?

Steve Beard: Yes, I think there were two significant changes in the final rule that we view as net positive for us. The first is that it included a transition period that allows programs to decrease tuition, adjust costs, scholarship students in a way that has an impact on the overall debt-to-earnings calculation. So that’s helpful. Just as importantly, they have provided a longer measurement period for certain types of programs. They’ve included medical programs and mental health programs, which is helpful to Chamberlain. So as we think about the rule, we’ve got opportunities to make adjustments to ensure that programs clear the hurdle for gainful employment. We are also actively seeking to have our veterinary medicine program included in those programs that have a longer measurement period, because their profiles are very similar to the programs that is included in that exception.

So a better outcome that will be feared with gainful employment. And obviously, we’ve got a bit of time before that, that goes into effect. The rule doesn’t go into effect until 2024 and the first measurement period isn’t until 2025. So we feel good about where we are vis-à-vis GE.

Jeffrey Meuler: Okay, perfect. And then just last one for me. Just can you address what the metrics are the drivers of the increasing letter of credit with the Department of Education or what you need to do, what outcomes you need to have to kind of alleviate that letter of credit?

Steve Beard: So as you know the composite score itself is a sort of bespoke calculation by the Department of Education. One of the nuances of the calculation is that, as they look at financial responsibility, you get credit for some assets and not for others. One of the assets that gets excluded or one category of asset that gets excluded from the calculation are intangible assets like goodwill. We obviously hung a bunch of goodwill on the balance sheet as part of the Walden acquisition and that drives down the score. That was not unexpected and the request for the additional letter of credit was not unexpected, and we managed our credit facility in a way that would commit us to accommodate its request. But that having been said, we actually think that with the existing letter of credit plus the new letter of credit, we’ve got a credit protection at that it’s almost 20% of our [indiscernible] disbursements.

We are actually working with Ed to see if there’s a way to bring that requirement down a bit because there isn’t any real risk to any of our institutions. We are a very financially healthy organization. None of our institutions are at risk of closure. We’ve got strong balance sheet. So we think the corks of the rule while they produce this outcome, we actually think there’s a good argument to be had for a somewhat lighter credit requirement at Ed. As for score itself, I’ll let Bob give you the specifics, but basically, we would earn our way out of the score and the score would go up over time on the basis of our earnings, because the calculation is done annually on the basis of our audited financial statements. But that’s not something that would happen immediately.

That’s something that would happen over time. But I think the important takeaway is that we are organized financially such that we can accommodate this request from Ed. And we think we have good arguments for why the ask here is probably larger than what Ed needs to be comfortable about the financial responsibility of our institutions and programs.

Jeffrey Meuler: Okay. Thank you.

Steve Beard: Sure.

Operator: Thank you. Our next question comes from the line of Jeff Silber with BMO Capital Markets. Please proceed with your question.

Ryan Griffin: Hi. Thank you. This is Ryan on for Jeff. On the guidance revisions, does the higher outlook include any more incremental investment in the growth with purpose initiative from what you had said last quarter? I was just thinking that given some of the operating leverage in the business, the adjusted EPS impact on the revenue rate would be a little bit higher.

Bob Phelan: Yes, let me address that if I could. The first thing I would say is that, yes, it’s a good point that you’re raising. And what I would say is that, first off, the improvement that we saw in the first quarter is really — there’s a little bit of a shift in terms of what we had in terms of the Growth with Purpose expenses going into the second quarter. So a little bit of that is a shift in timing with the expenses. We also did anticipate we were going to have a little bit higher expenses in the first place in the second quarter. So we have that as well. The other thing I was going to mention is that while the EPS would increase from the additional revenue, you also have a decrease coming from the additional interest expense on the letter of credit that Steve was just talking about that we’ve had to put in.

So that letter of credit is going to be about $158 million, a little bit under 4% rate. And so that’s going to cost us about $4 million this year and $6 million on an annualized basis. So I think that’s a part of what you would need to factor in as well.

Ryan Griffin: Got it. And then just any updated thoughts, sorry if I missed this on the pacing of the investments throughout the year. Is it still second half weighted? And would you consider giving us any sequential persistence or other ROI metrics on some of the spend there in future quarters?

Steve Beard: So what I would mention is that, as I just had said, we are having a little bit more of a shift of some of those expenses into the second quarter from the first, okay? So that’s one point that I would make. But when it comes to the acceleration of revenue, we still believe that the back half is where we are going to see more of a ramp up from the initiatives that we’ve implemented at this point.

Ryan Griffin: Got it. Thank you. And then just the last question for me. Do you have any color you could give on some of the pricing? I noticed in the Q that you’re taken pricing up quite a bit in some of the med schools and the revenue per student at Walden. It looks like it went up a bit on the — I think you mentioned the optimization of the student pricing.